Literature DB >> 8741139

Guillain-Barré syndrome in South-West Stockholm, 1973-1991, 3. Clinicoepidemiological subgroups.

J de Pedro-Cuesta1, V Abraira, G X Jiang, G Solders, S Fredrikson.   

Abstract

Using hierarchical cluster analysis, applied to 47 cases of Guillain-Barré Syndrome (GBS) incident in South-West Stockholm (SWS) during the period from January 1973 to June 1992, we identified three major clinicoepidemiological subgroups. The first subgroup, 25.5% of the cases (26.7 +/- 6.7 years), recorded a peak incidence at ages 20-29 years and presented significant differences from other subgroups, a high proportion of cases with onset at low age preceded by respiratory infection (83.3%) and with normal motor conduction velocity (50.0%). Also found, were less affected biological parameters, a rapidly progressive course and independence in gait at one month after onset. A second subgroup, 27.7% of cases, was severely affected, clinically and functionally. It consisted predominantly of young individuals (22.7 +/- 11.1 years), with a high incidence (69.2% of cases) in autumn. A third subgroup, comprising 40.4% of cases, was older (61.1 +/- 11.0 years) and, in general, also severely affected. The incidence of this form appeared to be invariant with time.

Entities:  

Mesh:

Year:  1996        PMID: 8741139     DOI: 10.1111/j.1600-0404.1996.tb00195.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Guillain-Barré syndrome in Stockholm County, 1973-1991.

Authors:  G X Jiang; Q Cheng; A Ehrnst; H Link; J de Pedro-Cuesta
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

3.  Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93.

Authors:  G X Jiang; Q Cheng; H Link; J de Pedro-Cuesta
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.